BURLINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in September.
Morgan Stanley 22nd Annual Global Healthcare Conference
Wednesday, September 4, 2024
New York Marriott Marquis, New York, NY
David Roberts, President, will present at 5:35 PM EST
Barrington Research Fall Investment Conference (Virtual)
Thursday, September 12, 2024
George W. LeMaitre, Chairman & CEO, is scheduled to host a series of 1x1 meetings
Cantor Fitzgerald 2024 Global Healthcare Conference
Thursday, September 19, 2024
InterContinental New York Barclay Hotel, New York, NY
David Roberts, President, will present at 8:00 AM EST
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. For more information about the Company, please visit www.lemaitre.com.
LeMaitre is a registered trademark of LeMaitre Vascular, Inc.
| Last Trade: | US$92.12 |
| Daily Change: | -0.13 -0.14 |
| Daily Volume: | 367,631 |
| Market Cap: | US$2.070B |
December 16, 2024 October 31, 2024 August 01, 2024 May 02, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
